Specific behaviour ‐ agitation · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Tremor · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tremor by 7 days compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
1 finding from 1 review
Diarrhoea · preschool and school‐age children
Point‐of‐use fortification of foods with micronutrients powders (MNP) showed no clear difference in diarrhoea (≥ 3 liquid stools per day) compared with no intervention or placebo (low certainty).
1 finding from 1 review
Absenteeism · employees
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · psychiatrists and people with schizoaffective disorder or schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change from baseline in mean asthma symptom score (daytime) Greater the reduction, better the outcome Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
All‐cause mortality, 30 days1 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in cardiovascular death, 30 days3 compared with placebo (low certainty).
1 finding from 1 review
AAA‐related death, 30 days4 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in AAA‐related death, 30 days4 compared with placebo (low certainty).
1 finding from 1 review
Nonfatal cardiovascular event, 30 days5 · patients of any age with AAA less than 30 mm in diameter
Metoprolol showed no clear difference in nonfatal cardiovascular event, 30 days5 compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · children with pleural empyema
1 finding from 1 review
Length of hospital stay · children and adults with pleural empyema
1 finding from 1 review
Intervention not reported
Serum creatinine: day 1 · patients undergoing a surgical intervention that induces kidney injury
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intervention not reported
Serum creatinine: day 2 · patients undergoing a surgical intervention that induces kidney injury
1 finding from 1 review
no estimate extracted
Studies not reported
High
Time away from normal activities (days) · patients with recurrence and pain in Lichtenstein inguinal hernioplasty
1 finding from 1 review
Mortality at 28 days · adult patients with sepsis, severe sepsis and septic shock
PCT showed no clear difference in mortality at 28 days compared with non‐PCT (standard care or CRP: primary outcomes) (low certainty).
1 finding from 1 review
Time receiving antimicrobial therapy (days) ‐ mean (SD) · adult patients with sepsis, severe sepsis and septic shock
1 finding from 1 review
Participants who required surgical incision and drainage after the treatment period or seven days after diagnosis · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review